Page URL:

Enzyme discovered critical to age-related cognitive decline

26 May 2020
Appeared in BioNews 1048

New research has led to the discovery of an enzyme that can help to reverse the DNA damage associated with ageing and Alzheimer's disease.

A joint study from Massachusetts Institute of Technology (MIT) and Harvard University has led to the identification of an enzyme, HDAC1, which is critical for repairing age-related DNA damage to genes involved in cognitive functions including memory, performance and spatial awareness. HDAC1 levels usually decline with normal ageing and are known to be lower in Alzheimer's patients.

'It seems that HDAC1 is really an anti-ageing molecule,' Professor Li-Huei Tsai, senior author of the study, told MIT News. 'I think this is a very broadly applicable basic biology finding, because nearly all of the human neurodegenerative diseases only happen during ageing. I would speculate that activating HDAC1 is beneficial in many conditions.'

Published in Nature Communications, the study has shown that genome-edited mice without HDAC1 have a specific type of DNA damage that builds up as the mice age. Furthermore, it was shown that this damage could be reversed by the administration of a drug that activates HDAC1, resulting in improved cognitive function in the mice.

The drug used to activate HDAC1 in this study is called exifone, which used to be approved to treat dementia in humans, but was withdrawn from use as it was found to lead to liver damage in some patients. However, the researchers believe that other drugs could be developed targeting HDAC1 to reverse cognitive decline.

Initially, the HDAC1 deficient mice showed no difference in DNA damage or behaviour as compared to the control group. However, the cognitive decline became clear in the HDAC1 deficient mice as they aged, showing an increase in DNA damage in their neurons. As a result, the mice performed worse in memory and spatial navigation tests.

Specifically, the HDAC1 deficient mice were discovered to have eight-oxo-guanine lesions, which is a type of DNA damage caused by oxidation. Interestingly, an increase in this type of DNA damage is found in patients with Alzheimer’s disease.

The scientists propose that promoting the activation of HDAC1 has implications for Alzheimer's patients and also people with age-related cognitive decline. 'This study really positions HDAC1 as a potential new drug target for age-related phenotypes, as well as neurodegeneration-associated pathology and phenotypes,' said Professor Tsai. Her lab is continuing their research to determine whether DNA damage and HDAC1 also play a role in the formation of Tau tangles, misfolded proteins in the brain, a hallmark characteristic of neurodegenerative diseases such as Alzheimer's.

29 June 2020 - by Dr Helen Robertson 
A genetic variant may drive the early formation of amyloid plaques, aggregates of misfolded proteins that form in the spaces between nerve cells, in the brain in Alzheimer’s disease...
29 October 2018 - by Martha Henriques 
A pattern of epigenetic alteration of genes involved in Alzheimer's disease has been discovered...
4 December 2017 - by Ewa Zotow 
Researchers have discovered a gene which may reduce the risk of developing Alzheimer's disease...
20 January 2014 - by Dr Katie Howe 
Researchers have identified a class of drug that helps clear traumatic memories in mice. The drug may help improve the effectiveness of behavioural therapy in the treatment of post traumatic stress disorder...
30 September 2013 - by Rhys Baker 
Whether painful memories linger or fade may be down to the expression of a single gene, according to researchers at Massachusetts Institute of Technology (MIT), USA...
5 March 2012 - by Dr Maria Botcharova 
An enzyme associated with memory loss can be blocked to reverse symptoms of Alzheimer's disease in mice, a study has shown...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.